Company Celadon Pharmaceuticals Plc

CEL

GB00BDQYGP38

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:13 01/05/2024 BST			5-day change	1st Jan Change
100 ^GBX	+2.04%		-13.04%	-13.04%

03-08	Celadon hails early results of chronic pain trial	AN
03-07	Celadon Pharmaceuticals plc Announces the Results of an Early Economic Analysis of the Data Collected as Part of the Feasibility Study for Its Fully Approved Chronic Pain Clinical Trial	CI

Celadon Pharmaceuticals Plc is a United Kingdom-based pharmaceutical company. The Company is engaged in research, cultivation, manufacturing, and supply of cannabinoid-based medicines. The Company is focused on growing indoor hydroponic cannabis initially for the chronic pain market. It is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions, such as autism. The Company's facility comprises an indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. It also has a minority interest in early-stage biopharma Kingdom therapeutics. The Company's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.

Number of employees: 24

Managers	Title	Age	Since
James Short FOU	Founder	55	31/12/17
Jonathan Turner DFI	Director of Finance/CFO	46	16/01/23
Iqbal Gill CTO	Chief Tech/Sci/R&D Officer	-	-
Arthur Wakeley PRN	Corporate Officer/Principal	-	-
Burleigh Abbott PRN	Corporate Officer/Principal	-	-
Kerin Williams SEC	Corporate Secretary	46	-

Members of the board	Title	Age	Since
David Firth BRD	Director/Board Member	62	-
Ian Anton CHM	Chairman	64	27/03/22
Robert Barr BRD	Director/Board Member	65	27/03/22
Steven Hajioff BRD	Director/Board Member	58	27/03/22
Jonathan Turner DFI	Director of Finance/CFO	46	16/01/23
James Short FOU	Founder	55	31/12/17
Elizabeth Shanahan BRD	Director/Board Member	59	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	64,208,903	21,738,143 ( 33.86 %)	0	33.86 %

Name	Equities	%	Valuation
James Short 40.57 %	26,046,928	40.57 %	28 M p
Cormac Short 7.048 %	4,525,403	7.048 %	5 M p
Paul Allen 7.048 %	4,525,403	7.048 %	5 M p
Jonathan Rickard 3.506 %	2,251,388	3.506 %	2 M p
Ian Anton 2.055 %	1,319,569	2.055 %	1 M p
Benjamin Shaw 0.7787 %	500,000	0.7787 %	530 565 p
Robert Barr 0.0708 %	45,454	0.0708 %	48 233 p
David Firth 0.0189 %	12,121	0.0189 %	12 862 p

Celadon Pharmaceuticals Plc

32-33 Cowcross Street

EC1M 6DF, London

http://www.summerwaycapital.co.uk

address Celadon Pharmaceuticals Plc(CEL)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1 GBP

Average target price

2.35 GBP

Spread / Average Target

+135.00%

Consensus

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
CELADON PHARMACEUTICALS PLC	-13.04%	78.81M
ELI LILLY AND COMPANY	+33.25%	704B
NOVO NORDISK A/S	+28.59%	577B
JOHNSON & JOHNSON	-3.55%	348B
MERCK & CO., INC.	+18.16%	327B
ABBVIE INC.	+4.36%	288B
ASTRAZENECA PLC	+14.81%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.69%	147B

Other Pharmaceuticals